Worm.com

M2 PRESSWIRE-28 February 2007-iQuate: New iQuate Software Eases Anti-Virus Management Headaches(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:28022007 Dublin, Ireland - iQuate, a leading provider of software that enables IT services, today announced the release of iQNetScan 6, the latest version of its clientless PC inventory and IT asset management suite.

Traditionally regarded as a leading IT compliance and risk management solution, the latest release of iQNetScan contains new functionality that extends the capabilities of traditional anti-virus management consoles. iQNetScan will …

Read the rest of this article with a Free Trial at HighBeam Research.

Information provided by: Findarticles.com

SAN DIEGO — Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, announced today that it executed a research collaboration with The Southwest Foundation for Biomedical Research (SFBR) to study the Aethlon Hemopurifier([R]) as a potential treatment for Lassa Fever. Lassa Fever is classified a category "A" bioterror threat in the United States, and is an endemic viral condition in Africa. Category "A" bioterror threats are defined by The Centers for Disease Control and Prevention (CDC) as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; could cause public panic and social disruption, and require special action for public health preparedness.

The studies will be performed at the nations only privately owned bio-safety level-4 (BSL-4) laboratory, located at the SFBR. BSL-4 facilities allow for the study of Lassa and other highly hazardous infectious agents requiring maximum containment. In addition to the SFBR collaboration, Aethlon initiated Hemopurifier([R]) studies with researchers at both the CDC and The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in January, and entered into a research partnership with the Government of India in December. Data obtained in these studies will be included in submissions with The Food and Drug Administration (FDA) and other government agencies.

About The Southwest Foundation for Biomedical Research

The Southwest Foundation for Biomedical Research (SFBR) is one of the world’s leading independent research organizations. It is home to the only privately owned bio-safety level-4 (BSL-4) laboratory in the United States. This maximum containment lab allows for research on lethal pathogens for which there are no treatments or vaccines, including bioterror and emerging pandemic threats. The SFBR, located on a 332-acre campus in San Antonio, Texas, partners with researchers around the world, targeting advances in heart disease, diabetes, obesity, cancer, hypertension, psychiatric disorders, premature newborn diseases, AIDS, hepatitis, malaria, and bioterror and emerging pandemic threats. Addition details can be accessed online at www.sfbr.org/pages/about_SFBR.php. Details specific to the SFBR BSL-4 research lab are available at www.sfbr.org/pages/about_resources2.php.

About Aethlon Medical

Aethlon Medical has developed a first-in-class medical device to treat infectious disease. The device, known as the Hemopurifier([R]), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, awarded Aethlon the 2006 Technology Innovation Award for its advances in the field of biodefense. The company has also initiated research on a second generation Hemopurifier([R]) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.

COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

M2 PRESSWIRE-28 February 2007-VDACS: Horse from Virginia tests positive for equine Herpes Virus-1(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:27022007 The Virginia Department of Agriculture and Consumer Services (VDACS) announced this afternoon that a horse from a farm in Loudoun County tested positive for Equine Herpes Virus-1 (EHV-1).

This is the fifth horse from Virginia to test positive. Results on an additional horse, from Fauquier County, were negative. The latest positive test came from a horse that was at the Marion duPont Equine Medical Center (EMC) for treatment when …

Read the rest of this article with a Free Trial at HighBeam Research.

Information provided by: Findarticles.com

The first broad national snapshot of human papillomavirus infection shows that two dangerous strains covered by the new cervical-cancer vaccine infect just 2 percent of females ages 14 to 59, a lower prevalence than previously estimated.

Even among women most likely to be infected - sexually active 18- to 25-year-olds - these two cancer-causing HPV strains were relatively uncommon, infecting 3.5 percent.

Experts say these findings, published today, do not change the conclusion that the public-health benefits of vaccination are worth the cost.

But the new data may create confusion and fuel controversy over whether to mandate inoculation of pubescent girls. At least 20 states are considering proposals.

The study supports the notion that there should not be a “rush to make this vaccine mandatory,” said Kenneth Chaiken, a Dallas lawyer representing six parents who are suing the Texas governor over his order requiring vaccination of …

Information provided by: Findarticles.com

M2 PRESSWIRE-27 February 2007-VDACS: Horse from Virginia tests positive for Equine Herpes Virus-1(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:26022007 The Virginia Department of Agriculture and Consumer Services (VDACS) announced that a horse from a farm in Fauquier County tested positive for Equine Herpes Virus-1 (EHV-1).

This horse had been admitted to the Marion duPont Scott Equine Medical Center (EMC) for surgery and went to a convalescent center in Maryland to recuperate. She had to be euthanized because of complications from surgery, but test results revealed she also was …

Read the rest of this article with a Free Trial at HighBeam Research.

Information provided by: Findarticles.com

CHICAGO — One in four U.S. women ages 14 to 59 is infected with the sexually transmitted virus that in some forms can cause cervical cancer, according to the first broad national estimate.

The figure is mostly in line with previous assessments. The highest prevalence — nearly 45 percent — was found in young women within the age range recommended for a new virus-fighting vaccine, according to a report from the federal Centers for Disease Control and Prevention.

Researchers have estimated that 20 million Americans have some form of HPV. The study concluded that 26.8 percent of U.S. women are infected, a figure that is comparable to earlier estimates using smaller groups.

“We expected the prevalence of any HPV infection would be high and that’s what we found,” said CDC researcher Dr. Eileen Dunne, the study’s lead author.

Just 3.4 percent of the women studied had infections with one of the four HPV strains that the new vaccine protects against. But that doesn’t mean the vaccine should be written off, said Dr. Yvonne Collins, an assistant professor of gynecologic cancer at the University of Illinois at Chicago.

For one thing, Collins said, that relatively small percentage corresponds with a lot of women — about 3 million, according to the report. And it does not include those with past infections that have cleared up.

The number of women with HPV strains targeted by the vaccine was lower than in some previous, less comprehensive estimates. And the overall HPV prevalence among the youngest women studied, 14- to-24- year-olds, was substantially higher than in previous estimates, 7.5 million versus 4.6 million.

Dunne attributed those variations to different study populations and different HPV detection methods. She said the results should not be interpreted to mean infection prevalence has changed in recent years.

The new nationally representative report is based on vaginal swab specimens from 1,921 women tested in 2003-04.

The report appears in Wednesday’s Journal of the American Medical Association.

There are dozens of strains of HPV. Low-risk forms can cause genital warts and non-cancerous changes in cells in the cervix, and often clear without treatment. Several high-risk forms have been linked with cervical cancer.

Dunne said HPV prevalence is thought to be high in men as well, but none were studied.

An estimated 11,150 U.S. women will be diagnosed this year with cervical cancer, and about 3,670 will die from it. Numbers are much higher worldwide, especially in developing countries where Pap tests to detect cervical cancer are not routine.

The new vaccine, Merck’s Gardasil, was approved last June for girls and women aged 9 to 26. It protects against two HPV strains believed responsible for about 70 percent of cervical cancer cases, and two other strains that cause 90 percent of genital wart cases.

Other vaccines are in the works to protect against other HPV strains, Collins said.

Women aged 20 to 24 had the highest overall HPV prevalence in the study, 44.8 percent. Prevalence increased each year from ages 14 to 24, then dropped off gradually, confirming that young, sexually active women face the greatest risk of infection.

The study underscores the need for young women to get vaccinated, and to get routine Pap tests, said Dr. Howard Jones, a gynecologic cancer specialist at Vanderbilt University.

c2007 ANG Newspapers. Cannot be used or repurposed without prior
written permission.
Provided by ProQuest Information and Learning Company. All rights Reserved.

Information provided by: Findarticles.com

WASHINGTON (AFP) — About a quarter of females in the United States aged 14 to 59 may have the sexually transmitted infection human papillomavirus, which is linked to cervical cancer, according to research published Tuesday.

“Our study provides the first national estimate of prevalent HPV infection among females aged 14 to 59 years in the United States,” said the team of scientists led by Eileen Dunne of the federal Centers for Disease Control and Prevention, writing in an article in the Journal of the American Medical Association dated February 28.

HPV is the most commonly sexually transmitted infection in the United States.

“Our data indicate that the burden of prevalent HPV infection among women was higher than previous estimates,” they wrote.

The most virulent types of HPV can cause cervical, anal and other genital cancers. HPV types 16 and 18 are responsible for about 70 percent of cervical cancers worldwide, …

Information provided by: Findarticles.com

Byline: Gregory Lopes, THE WASHINGTON TIMES The chairman of the federal panel that recommended the new cervical-cancer vaccine for pre-teen girls says lawmakers should not make the inoculation mandatory, as the District and more than 20 states, including Virginia, are considering. Dr. Jon Abramson, chairman of the Centers for Disease Control and Prevention’s advisory committee on immunization practices (ACIP), also said he and panel members told Merck & Co., the drug Gardasil’s maker, not to lobby state lawmakers to require the vaccine for school attendance.

"I told …

Read the rest of this article with a Free Trial at HighBeam Research.

Information provided by: Findarticles.com

Fortinet — the pioneer and leading provider
of unified threat management (UTM) solutions — today announced that its
FortiClient(TM) end-point security software has earned its fifth
consecutive Virus Bulletin 100% award for its best-in-class antivirus
capabilities. In this test, for antivirus products running on Microsoft
Vista(TM), FortiClient earned 100 percent marks in every possible award
category. The product was also specifically recognized for its reliability
and performance.

Well-known in the industry, the Virus Bulletin (VB) 100% awards recognize
products that have been tested by independent experts and proven to
accurately detect 100 percent of viruses known to be “in the wild,”
constituting current, real-world viruses.

Virus Bulletin staff tested FortiClient 3.0 along with 15 other antivirus
products for their detection rates, lack of false positives and speed of
scanning. This latest VB 100% award adds to Fortinet’s impressive and
unmatched portfolio of technology certifications and accolades — including
five VB 100% awards, two NSS certifications (IPS, UTM) and eight ICSA
certifications (firewall, antivirus, IPSec, SSL, Network IPS, client
antivirus detection, cleaning and antispyware).

“It is imperative that security vendors are prepared to protect their users
against attacks leveraging potential Microsoft Vista security holes,” said
Michael Xie, Fortinet founder, CTO and vice president of engineering.
“Receiving such high marks on the Virus Bulletin 100% Microsoft Vista test
further proves that we are able to anticipate the needs of our customers
and provide the malware protection that they require.”

Fortinet’s FortiClient(TM) host security software, which now supports both
32-bit and 64-bit versions of Microsoft Vista, addresses the need for
secure access and endpoint protection for telecommuters, mobile workers,
remote sites and partners. A unified security agent for personal computers
and mobile devices, FortiClient integrates host antivirus, host
antispyware, a personal firewall, antispam, IPSec VPN, web content
filtering and registry monitoring. FortiClient supports the most popular
Microsoft Windows(TM) operating systems natively and also includes network
address translation (NAT) traversal, centralized policy management,
multiple policy support for access to multiple devices, strong encryption,
and a comprehensive set of tools for troubleshooting. The latest version of
FortiClient also now supports 64-bit for both Microsoft Windows XP(TM) and
Windows 2003 Server. Designed to extend real-time protection to the desktop
and mobile users, FortiClient automatically removes viruses, spyware, worms
and other network threats by scanning and cleaning both incoming and
outgoing email messages.

For a 90-day evaluation of FortiClient end point security software, visit:
http://www.download.com/FortiClient/3000-2653_4-10536755.html?tag=lst-0-1 .
Or, visit http://www.fortinet.com/products/forticlient.html for more
information.

About Fortinet ( www.fortinet.com )

Fortinet is the pioneer and leading provider of ASIC-accelerated
multi-threat security systems, which are used by enterprises and service
providers to increase their security while reducing total operating costs.
Fortinet solutions were built from the ground up to integrate multiple
levels of security protection — including firewall, antivirus, intrusion
prevention, VPN, spyware prevention and antispam — providing customers a
way to protect multiple threats as well as blended threats. Leveraging a
custom ASIC and unified interface, Fortinet solutions offer advanced
security functionality that scales from remote office to chassis-based
solutions with integrated management and reporting. Fortinet solutions have
won multiple awards around the world and are the only security products
that are certified eight times over by ICSA Labs (firewall, antivirus,
IPSec, SSL, IPS, client antivirus detection, cleaning and antispyware).
Fortinet is privately held and based in Sunnyvale, California.

Fortinet is a registered trademark of Fortinet, Inc. Fortinet, FortiGate,
FortiOS, FortiAnalyzer, FortiASIC, FortiCare, FortiManager, FortiWiFi,
FortiGuard, FortiClient, and FortiReporter are trademarks of the Fortinet,
Inc. in the United States and/or other countries. All other trademarks
referred to herein are the property of their respective owners.

Media Contact:
Jennifer Leggio
Fortinet, Inc.
+1 408 486 7876
jleggio@fortinet.com

Information provided by: Findarticles.com

M2 PRESSWIRE-26 February 2007-VDACS: Update on Equine Herpes Virus-1 in Virginia, additional facilities quarantined as a precaution(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:23022007 The Virginia Department of Agriculture and Consumer Services (VDACS) is taking precautionary measures and quarantining additional farms in Virginia due to an outbreak of Equine Herpes Virus-1 (EHV-1).

Previously, VDACS quarantined the Marion duPont Scott Equine Medical Center (EMC) in Leesburg and one farm in Loudoun County. In the hours following discovery of a horse possibly infected with EHV-1 …

Read the rest of this article with a Free Trial at HighBeam Research.

Information provided by: Findarticles.com